Chen Shimin, Lin Jichun, Zhao Jiaojiao, Lin Qian, Liu Jia, Wang Qiang, Mui Ryan, Ma Leina
Department of Oncology, Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
Qingdao Cancer Institute, Qingdao, China.
Front Oncol. 2023 Mar 14;13:1147239. doi: 10.3389/fonc.2023.1147239. eCollection 2023.
FBXW7 (F-box and WD repeat domain containing 7) is a critical subunit of the Skp1-Cullin1-F-box protein (SCF), acting as an E3 ubiquitin ligase by ubiquitinating targeted protein. Through degradation of its substrates, FBXW7 plays a pivotal role in drug resistance in tumor cells and shows the potential to rescue the sensitivity of cancer cells to drug treatment. This explains why patients with higher FBXW7 levels exhibit higher survival times and more favorable prognosis. Furthermore, FBXW7 has been demonstrated to enhance the efficacy of immunotherapy by targeting the degradation of specific proteins, as compared to the inactivated form of FBXW7. Additionally, other F-box proteins have also shown the ability to conquer drug resistance in certain cancers. Overall, this review aims to explore the function of FBXW7 and its specific effects on drug resistance in cancer cells.
FBXW7（含F盒和WD重复结构域7）是Skp1-Cullin1-F盒蛋白（SCF）的关键亚基，通过对靶向蛋白进行泛素化作用充当E3泛素连接酶。通过降解其底物，FBXW7在肿瘤细胞的耐药性中起关键作用，并显示出恢复癌细胞对药物治疗敏感性的潜力。这就解释了为什么FBXW7水平较高的患者具有更长的生存时间和更良好的预后。此外，与失活形式的FBXW7相比，FBXW7已被证明可通过靶向特定蛋白的降解来增强免疫治疗的疗效。此外，其他F盒蛋白在某些癌症中也显示出克服耐药性的能力。总体而言，本综述旨在探讨FBXW7的功能及其对癌细胞耐药性的具体影响。
